Welcome, and thank you for accessing our Media Room, which is your gateway to relevant information about the HIV Vaccine Trials Network (HVTN). We are a team of people on a scientific journey to find an effective preventive HIV vaccine. Our work is made possible through the commitment of our heroes – individuals, families, and communities around the world who contribute to the success and impact of our work.
Recent Press Releases
Developing an effective HIV vaccine is the “key step forward” we have been pursuing as a global community to halt one of humankind’s most formidable foes. Read more >
Researchers used a dynamic economic mathematical model to show that five-dose series HIV vaccine campaigns rolled out every two years, in the country with the highest number of daily new HIV infections (South Africa), would provide great health benefits and be potentially cost-effective. Read more >
The Nelson Mandela Academic Clinical Research Unit (NeMACRU) in Mthatha, South Africa became part of a network of clinical trial sites that are conducting the largest Phase 2b/3 HIV vaccine efficacy clinical trial in the country. Read more >
An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection. These findings from the ongoing Phase I/II HVTN 100 study were published on June 10 in Lancet HIV. Read more >
Neither frequency of alcohol use, binge drinking, marijuana, nor other drug use negatively impacts retention and adherence rates in phase I clinical trials of preventive HIV vaccines. These were the findings revealed in a meta-analysis performed by an HIV Vaccine Trials Network (HVTN) Research and Mentorship Program (RAMP) scholar to assess the patterns of substance use among enrolled participants, and the impact substance use has on retention in phase 1 preventive HIV vaccine clinical trials. Read more >